1 Sept Health Department packaging alert puts UAE pharmacy substitution workflows under review

South Africa's Department of Health said on 1 September 2026 that medicine colour, shape, packaging or manufacturer changes do not mean treatment has changed, a message UAE clinics, pharmacies and insurers should treat as an operating-risk reminder rather than a distant public-sector story.

The highest-stakes readers are COOs, CFOs and medical directors. In Dubai, any similar confusion lands first at the pharmacy counter, clinic call centre and insurer pre-approval desk. The relevant UAE regulators are the Dubai Health Authority (DHA) for Dubai, the Department of Health Abu Dhabi (DOH) for Abu Dhabi and Al Ain, and the Ministry of Health and Prevention (MOHAP) for Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain.

What the South African statement said

IOL reported that the department had received public concerns about medicines appearing out of stock and patients receiving products that looked different from previous supplies. Foster Mohale, spokesperson for South Africa's Department of Health, said patients should not assume a shortage or a treatment change when an equivalent medicine is dispensed.

"A change in the colour, shape, packaging or manufacturer of a medicine does not mean that the medicine itself has changed," Foster Mohale, spokesperson for South Africa's Department of Health, said, according to IOL.

The department said public healthcare facilities source medicines from multiple approved suppliers. It also said shortages may involve a specific brand, supplier or pack size while an equivalent product remains available. The operational point is narrow: the patient sees a different box, tablet or manufacturer; the pharmacist sees the same active ingredient, strength and therapeutic purpose.

Why this matters in Dubai and Abu Dhabi

UAE providers face the same patient-confidence problem when supply changes occur. A chronic-disease patient who receives a different-looking medicine for diabetes, hypertension, asthma or anticoagulation may skip doses, call the clinic, reject delivery or ask the insurer to reverse a claim. The cost is time, adherence and avoidable rework.

For Dubai operators, the practical control point is the DHA-licensed pharmacy and the dispensing record. DHA's pharmacy guidelines require the facility licence to state the facility name, address, licence validity and pharmacist-in-charge. The same DHA document says a pharmacy seeking 24-hour service needs four licensed DHA pharmacists, including one full-time pharmacist. That makes staffing a supply-continuity and HR issue.

In Abu Dhabi, DOH lists more than 950 pharmacies operating in the emirate on its public website. DOH also provides a pharmacy search tool through its Lists and Tools page. For the northern emirates, MOHAP maintains a medical facilities directory that includes pharmacy and medical warehouse categories.

What operators should check this week

The UAE does not need a shortage headline for this issue to hit operations. It can appear as a claims query, a complaint on a delivery app, a call to a clinic nurse or a medication-safety incident. Daman, Thiqa and Sukoon processes should be checked only against the relevant policy, network contract and formulary rule, because substitution handling differs by product, plan and prior-approval status.

• Clinics: confirm that prescribers write the generic name where clinically appropriate and document brand-specific reasons when substitution is unsafe.
• Pharmacies: brief counter staff to explain active ingredient, strength and dosage when packaging changes, and record patient refusal as a traceable event.
• Insurers: test whether claims systems reject a reimbursable equivalent because the brand, pack size or supplier code changed.
• Medical directors: review high-risk classes, including anticoagulants, insulin, anticonvulsants and transplant medicines, before allowing routine substitution.

Price is the second control point. MOHAP publishes medicine price information in AED and the UAE's Emirates Drug Establishment lists a medical products price-list service with a stated completion time of 3 to 5 working days and a 500 dirham fee. Operators should use the official price list, insurer portal and pharmacy invoice rather than relying on informal AED ranges for prescription products.

The next UAE risk is communication. A one-page script for pharmacists and call-centre staff can prevent a packaging change from becoming a suspected shortage. It should tell patients the active ingredient, strength, dosing schedule, manufacturer change and regulator-licensed dispensing location. Patients and operators can verify licensed pharmacy providers through the UAE Open Healthcare Directory and the official DHA, DOH and MOHAP directories.